| 2013 | A patient-specific model of virtual ablation for atrial fibrillation | Conference Proceedings : Engineering in Medicine and Biology Society (EMBC) |
| 2007 | A peroxisome-proliferator activated receptor-γ ligand could regulate the expression of leptin receptor on human hepatic stellate cells | HISTOCHEMISTRY AND CELL BIOLOGY |
| 2017 | A Personalized and Learning Approach for Identifying Drugs with Adverse Events
| YONSEI MEDICAL JOURNAL |
| 2021 | A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer | INVESTIGATIONAL NEW DRUGS |
| 2017 | A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors | INVESTIGATIONAL NEW DRUGS |
| 2022 | A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
| JOURNAL OF THORACIC ONCOLOGY |
| 2022 | A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer | EXPERT OPINION ON INVESTIGATIONAL DRUGS |
| 2022 | A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma | ANNALS OF ONCOLOGY |
| 2023 | A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B | LIVER INTERNATIONAL |
| 2020 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
| GASTRIC CANCER |
| 2016 | A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus | JOURNAL OF VIRAL HEPATITIS |
| 2010 | A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer | INVESTIGATIONAL NEW DRUGS |
| 2012 | A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy | INVESTIGATIONAL NEW DRUGS |
| 2013 | A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas | INVESTIGATIONAL NEW DRUGS |
| 2011 | A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. | LUNG CANCER |
| 2023 | A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
| CANCER RESEARCH COMMUNICATIONS |
| 2013 | A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC) | LUNG CANCER |
| 2022 | A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation | ANNALS OF ONCOLOGY |
| 2018 | A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
| BMC CANCER |
| 2010 | A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. | ANTI-CANCER DRUGS |
